Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor

Investor Presentation Conference Call 6th July, 2020

Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020

JP Morgan Healthcare Conference, San Francisco, 15th January 2020

Linzagolix Phase 3 PRIMROSE 2 Trial Results

Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019

Cantor Global Healthcare Conference October 4 2019

The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019

1 2 3

Press Releases

ObsEva Announces Pricing of Follow-on Public Offering

press release

June 20, 2018

Geneva, Switzerland and Boston, MA – June 20, 2018– ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…

Read more

ObsEva Announces Launch of Proposed Follow-on Public Offering

press release

June 18, 2018

Geneva, Switzerland and Boston, MA – June 18, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and…

Read more

ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis

press release

Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being…

Read more
1 63 64 65 66 67 86

General Meetings

ObsEva Annual General Meeting 2021

May 28, 2021

Read more

ObsEva Annual General Meeting 2020

June 9, 2020

Read more
1 2 3 4

Upcoming Events

Annual General Meeting: Thursday 27 June, 2024

Event


    Read more
     

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    Investor relations


    IR@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    contact@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue